NCT05992428

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

An Open-label, 2-Part, Phase 1 Clinical Trial to Evaluate Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This is an open-label, 2-Part, phase 1 study to evaluate drug interactions when DA-8010 is co-administered with Paroxetine or Mirabegron in healthy adult subjects

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	DA-8010 5mg	\[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
DRUG	Paroxetine 20mg	\[Part 1\] DA-8010 5mg + Paroxetine 20mg
DRUG	Mirabegron 50mg	\[Part 2\] DA-8010 5mg + Mirabegron 50mg

Timeline

• Start date: 2023-08-22
• Primary completion: 2023-11-07
• Completion: 2023-12-05
• First posted: 2023-08-15
• Last updated: 2024-01-25

Locations

1 site across 1 country: South Korea